NEUPHORIA THERAPEUTICS INC (NEUP) Fundamental Analysis & Valuation

NASDAQ:NEUP • US64136E1029

4.73 USD
-0.01 (-0.21%)
Last: Mar 12, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This NEUP fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

Overall NEUP gets a fundamental rating of 3 out of 10. We evaluated NEUP against 519 industry peers in the Biotechnology industry. The financial health of NEUP is average, but there are quite some concerns on its profitability. NEUP is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. NEUP Profitability Analysis

1.1 Basic Checks

  • In the past year NEUP has reported negative net income.
  • NEUP had a negative operating cash flow in the past year.
  • In the past 5 years NEUP always reported negative net income.
  • In the past 5 years NEUP reported 4 times negative operating cash flow.
NEUP Yearly Net Income VS EBIT VS OCF VS FCFNEUP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M -25M

1.2 Ratios

  • NEUP has a better Return On Assets (-15.48%) than 79.38% of its industry peers.
  • Looking at the Return On Equity, with a value of -19.07%, NEUP belongs to the top of the industry, outperforming 83.24% of the companies in the same industry.
Industry RankSector Rank
ROA -15.48%
ROE -19.07%
ROIC N/A
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NEUP Yearly ROA, ROE, ROICNEUP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50 -100

1.3 Margins

  • NEUP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NEUP Yearly Profit, Operating, Gross MarginsNEUP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. NEUP Health Analysis

2.1 Basic Checks

  • NEUP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • NEUP has less shares outstanding than it did 1 year ago.
  • NEUP has less shares outstanding than it did 5 years ago.
  • NEUP has a better debt/assets ratio than last year.
NEUP Yearly Shares OutstandingNEUP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M
NEUP Yearly Total Debt VS Total AssetsNEUP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • Based on the Altman-Z score of -4.03, we must say that NEUP is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of NEUP (-4.03) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.00 indicates that NEUP is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.00, NEUP perfoms like the industry average, outperforming 51.25% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -4.03
ROIC/WACCN/A
WACC8.89%
NEUP Yearly LT Debt VS Equity VS FCFNEUP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -50M -100M

2.3 Liquidity

  • NEUP has a Current Ratio of 9.04. This indicates that NEUP is financially healthy and has no problem in meeting its short term obligations.
  • NEUP has a better Current ratio (9.04) than 77.26% of its industry peers.
  • A Quick Ratio of 9.04 indicates that NEUP has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 9.04, NEUP is in the better half of the industry, outperforming 77.26% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.04
Quick Ratio 9.04
NEUP Yearly Current Assets VS Current LiabilitesNEUP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NEUP Growth Analysis

3.1 Past

  • NEUP shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -130.00%.
  • The Revenue has been growing by 247.24% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.41%
Revenue 1Y (TTM)N/A
Revenue growth 3Y334.33%
Revenue growth 5Y247.24%
Sales Q2Q%-100%

3.2 Future

  • The Earnings Per Share is expected to decrease by -104.33% on average over the next years. This is quite bad
  • NEUP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 42.50% yearly.
EPS Next Y-1180.52%
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.5%

3.3 Evolution

  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
NEUP Yearly Revenue VS EstimatesNEUP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2030 2031 2032 2033 0 100M 200M 300M
NEUP Yearly EPS VS EstimatesNEUP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

0

4. NEUP Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NEUP. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NEUP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NEUP Price Earnings VS Forward Price EarningsNEUP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NEUP Per share dataNEUP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4

4.3 Compensation for Growth

  • NEUP's earnings are expected to decrease with -104.33% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NEUP Dividend Analysis

5.1 Amount

  • NEUP does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEUP Fundamentals: All Metrics, Ratios and Statistics

NEUPHORIA THERAPEUTICS INC

NASDAQ:NEUP (3/12/2026, 8:00:56 PM)

4.73

-0.01 (-0.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-17
Earnings (Next)05-18
Inst Owners29.79%
Inst Owner Change665.76%
Ins Owners3.41%
Ins Owner ChangeN/A
Market Cap25.49M
Revenue(TTM)15.00M
Net Income(TTM)-5.66M
Analysts80
Price Target9.96 (110.57%)
Short Float %0.67%
Short Ratio0.79
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-88.74%
Min EPS beat(2)-225.89%
Max EPS beat(2)48.41%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-32.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-4.5%
EPS NY rev (1m)25.55%
EPS NY rev (3m)14.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.7
P/FCF N/A
P/OCF N/A
P/B 0.86
P/tB 1.55
EV/EBITDA N/A
EPS(TTM)-2.12
EYN/A
EPS(NY)-4.43
Fwd EYN/A
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS2.78
BVpS5.51
TBVpS3.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -15.48%
ROE -19.07%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.06%
ROA(5y)-36.63%
ROE(3y)-62.56%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.41
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.04
Quick Ratio 9.04
Altman-Z -4.03
F-Score6
WACC8.89%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-130%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%133.41%
EPS Next Y-1180.52%
EPS Next 2Y-267.84%
EPS Next 3Y-104.33%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3Y334.33%
Revenue growth 5Y247.24%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y42.5%
EBIT growth 1Y93.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-238.83%
EBIT Next 3Y-65.01%
EBIT Next 5YN/A
FCF growth 1Y86.83%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y86.83%
OCF growth 3YN/A
OCF growth 5YN/A

NEUPHORIA THERAPEUTICS INC / NEUP FAQ

What is the fundamental rating for NEUP stock?

ChartMill assigns a fundamental rating of 3 / 10 to NEUP.


What is the valuation status of NEUPHORIA THERAPEUTICS INC (NEUP) stock?

ChartMill assigns a valuation rating of 0 / 10 to NEUPHORIA THERAPEUTICS INC (NEUP). This can be considered as Overvalued.


Can you provide the profitability details for NEUPHORIA THERAPEUTICS INC?

NEUPHORIA THERAPEUTICS INC (NEUP) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for NEUP stock?

The Earnings per Share (EPS) of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -1180.52% in the next year.